blood cancer journals

Dose-limiting toxicities were reversible blurred vision and neuropathy. The incidence of ALL follows a bimodal distribution, with the first peak occurring in childhood and a second peak occurring around the age of 50.2 While dose-intensification strategies have led to a significant improvement in outcomes for pediatric patients, prognosis for the elderly remains very poor. The process of CAR T-cell therapy involves collecting T cells, introducing the CAR construct, and then an autologous transplant of the modified T cells back into the patient. Presentation can be nonspecific, with a combination of constitutional symptoms and signs of bone marrow failure (anemia, thrombocytopenia, leukopenia). This so called, Ph-like ALL has been associated with poor response to induction chemotherapy, elevated minimal residual disease and poor survival.13, 14, 27. The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells. CAR-Ts have also shown activity in adults with relapsed/refractory B-ALL. The treatment resulted in a CR in 9 of the patients, with 7 achieving complete MRD clearance at the end of re-induction.82 A phase 2 study in adults with relapsed/refractory disease evaluated the addition of epratuzumab to clofaribine/cytarabine. Recently, it has become standard practice to evaluate patients for minimal residual disease (MRD) using molecular techniques such as flow cytometry and PCR.28 Several studies have shown the importance of MRD in assigning risk.29, 30, 31, 32, 33, 34 Bruggemann et al.29 re-stratified standard-risk patients to low risk, intermediate risk and high risk with relapse rates of 0%, 47% and 94%, respectively, based on the persistence of elevated MRD, defined as >104. While 80% of ALL occurs in children, it represents a devastating disease when it occurs in adults. In a subsequent, multi-center trial HCVAD plus dasatinib achieve a 3-year OS of 71% in adult patients younger than 60.57 In addition, prior resistance to imatinib did not preclude a response to dasatinib.58 In addition, dasatinib was shown to be effective in inducing complete remission when used in combination with prednisone and intrathecal methotrexate.59 In the GIMEMA LAL1205 study,59 it was noted that the most common cause of relapse was a T315I mutation in the ABL kinase doman. However, in patients with a complete MRD response, there was no survival benefit to Allo-SCT over standard chemotherapy.163, Allo-SCT also should be considered in all patients that relapse, optimally after achieving a second CR (CR2). sharing sensitive information, make sure youre on a federal To obtain Blood Cancer Journal (Blood Cancer J.) and JavaScript. Cambridge University Press, pp 4866. In patients with relapsed/refractory ALL, particularly those with multiple relapses, toxicity of multi-agent cytotoxic therapy may be limiting. Bielorai B, Fisher T, Waldman D, Lerenthal Y, Nissenkorn A, Tohami T et al. InO has also been studied in frontline therapy in combination with low-intensity HCVAD for elderly patients >60 years.92 These patients are prone to adverse events from chemotherapy and have poorer outcomes than their younger counterparts. Nearly all of the patients developed cytokine release syndrome (CRS). If the CNS is involved, brain MRI should be performed. Former NBC News anchor Tom Brokaw is opening up about his cancer battle.. blood cancer journal. The ISSN (online) number for Blood Cancer Journal is 2044-5385. VSLI was well tolerated with a side effect profile similar to standard-formulation VCR, despite the massive cumulative doses of VCR achieved. In addition, six additional patients experienced a >95% reduction in peripheral blasts.98 In adults with relapsed/refractory disease, combotox led to reduction of peripheral blasts in all patients; however, a durable response was not seen as blast count rebounded quickly after the final dose of combotox.99 A phase I trial is recruiting patients to evaluate combotox in combination with cytarabine for adults with relapsed/refractory ALL ({"type":"clinical-trial","attrs":{"text":"NCT01408160","term_id":"NCT01408160"}}NCT01408160). In addition to disease characteristics at the outset, it has long been recognized that response to initial therapy predicts outcome. Immunoconjugates, such as inotuzumab ozogamicin, bind to leukemic cells, are internalized and release a cytotoxin that kills the leukemic cell; whereas dual-specific antibodies, such as blinatumumab, cause the direct activation of T cells against blasts. Submit Manuscript 2 Year IF 3 Year IF 4 Year IF 5 Year IF Real-Time IF IF Preditction Data Source SCImango Scopus Database Cites / Doc. The cytogenetic aberration with the greatest impact on prognosis and treatment is the presence of the Philadelphia chromosome, t(9;22). Nachman J, Siebel N, Sather H, Steinherz P, DeLaat C, Fryer D et al. Blood Cancer Journal proudly publishes Current Treatment Algorithms, an article type dedicated to providing clear, authoritative, concise treatment pathways for hematologic malignancies. Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies. Open access publication ensures that your work is easily discovered, accessed, and shared. However, toxicity was greatly improved by weekly dosing, with a significant reduction in fever, hepatotoxicity and veno-occlusive disease.89 A second phase 2 study of 35 patients with CD22+ ALL in second salvage or later showed similar complete response rate (66%) and median overall survival (7.4 months).90 Based on these results, Kantarjian et al.91 compared weekly dosing of InO to standard chemotherapy for relapsed/refractory ALL. The most frequent adverse events include fever, chills, neutropenia, anemia and hypogammaglobulinemia.3 More significant adverse events are rare, but include cytokine release syndrome, altered mental status and seizures.73 Death from sepsis that is thought to be treatment-related has been reported. Internet Explorer). Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Alvarnas JC, Brown PA, Aoun P, Ballen KK, Barta SK, Borate U et al. Publishes high quality articles about hematologic malignancies and related disorders. Maude SL, Barrett D, Teachey DT, Grupp. A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox: Phase I Study in Pediatric Acute Lymphoblastic Leukemia (ALL). It consists of four cycles of hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone alternated with four cycles of high dose cytarabine and methotrexate.44 CNS prophylaxis with 4-16 doses of intrathecal chemotherapy depending on predetermined risk of CNS disease. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD et al. Effective multidisciplinary care is required, 3 and integrative oncology (IO) may effectively alleviate cancer-related . Porkka K, Koskenvesa P, Lundan T, Rimpilainen J, Mustjoki S, Smykla R et al. Blood Cancer Journal (Blood Cancer J.) Proposals for the classification of the acute leukaemias. Journal Citation Score*:1.56. Bortezomib interactions with chemotherapy agents in acute leukemia. O'Brien S, Schiller G, Lister J, Damon L, Goldberg S, Aulitzky W et al. Hinman LM, Hamann PR, Wallace R, Menendez AT, Durr FE, Upeslacis J. The first of these is the bispecific anti-T-cell receptor/anti-CD19 antibody, blinatumomab. blood cancer journal. Faderl S, Kantarjian HM, Thomas DA, Cortes J, Giles F, Pierce S et al. Peter E. Newburger, MD, of the University of Massachusetts Medical School, Worcester, MA, serves as Editor-in-Chief. or orally (p.o.) Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. Nordlund J, Milani L, Lundmark A, Lonnerholm G, Syvanen AC. A Phase I study of Milademetan (DS3032b) in combination with - Nature Incurable but treatable: Understanding, uncertainty and impact in Cost comparison of post-remission strategies in younger and - Nature In addition, JAK1 and JAK2 mutations are found in approximately half of CRLF2-rearranged Ph-like ALL.12, 13, 14 Preclinical studies have suggested benefit of ruxolitinib for the treatment of Ph-like ALL and CRLF2-rearranged ALL.129, 130 In addition, ruxolitinib inhibited tumor growth in in vitro and in vivo models of T-ALL with a gain of function in IL-7 R-alpha subunit.131 A phase 2 trial of ruxolitinib with standard multi-agent chemotherapy is currently open for recruitment of children, adolescents and adults with newly diagnosed high-risk B-ALL with CRLF2 rearrangements ({"type":"clinical-trial","attrs":{"text":"NCT02723994","term_id":"NCT02723994"}}NCT02723994). Horton Terzah M, O'Brien Maureen Megan, Borowitz Michael J, Devidas Meenakshi, Raetz Elizabeth A, Brown Patrick Andrew et al. Updated results from phase II study of combination of hyper-CVAD (HCVAD) with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)[abstract]. XX. PBDs are a class of natural antibiotics derived from actinomycetes bacteria that inhibit cell division by binding in the minor groove of DNA and cross-linking strands of DNA. Archive of "Blood Cancer Journal". - PMC - National Center for Internet Explorer). In a phase 1 study of patients with relapsed/refractory B-ALL or aggressive B-cell lymphomas, a complete response rate of 35% was observed.120 Dosing interval of 3 weeks was shown to be superior to weekly dosing. DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia, DNA Methylation as a Therapeutic Target in Cancer. Jones D, Thomas D, Yin CC, O'Brien S, Cortes JE, Jabbour E et al. OS at 2-years was 78%.64 Similarly, The Group for Research on Adult Acute Lymphoblastic Leukemia (GRAAL), compared 225 patients up to the age of 60 who were treated on pediatric-inspired regimen and historical data from 712 adults treated on standard adult regimen LALA-93.36 They observed a significant improvement in CR, EFS and OS, which was most marked in patients younger than age of 45 years. Blood Cancer Discovery - Impact Factor & Score 2023 - Research.com In fact, in patients older than 45 years, there was a significantly higher rate of chemotherapy-related events compared to younger patients, suggesting that an age cutoff for pediatric-inspired regimens is appropriate. Blood Cancer Journal (Blood Cancer J.) Despite a reduction in CNS relapse and improved event-free survival, dexamethasone has increased risk of adverse events compared to prednisone. Lee et al.154 reported a 66.7%% CR rate in a National Cancer Institute (NCI) intent-to-treat analysis of 20 children and young adults with ALL, with a median CAR-T persistence of 68 days. Younes A, Kim S, Romaguera J, Copeland A, Farial Sdc, Kwak LW et al. Join the Blood Cancer Journal Twitter Community. [PMC free article] [Google Scholar] Scavino HF, George JN, Sears DA. Induction is divided into two phases of four weeks. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C et al. Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M et al. There remains much uncertainty about how best to treat adults with ALL, as some studies have shown benefit of pediatric-inspired regimens. It has long been reported that DNA methylation may play a role in the development of ALL and that methylation status may be used as part of risk stratification.132, 133, 134, 135 Decitabine is a cytosine analog that inhibits DNA methyltransferase by targeting it for degredation, thus causing hypomethylation of key regulatory domains on DNA. Sasaki K, Jabbour EJ, Ravandi F, Short NJ, Thomas DA, Garcia-Manero G et al. Hematology/Oncology - The New England Journal of Medicine Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Chessells J, Harrison G, Richards S, Bailey C, Hill F, Gibson B et al. Safety and clinical activity of 5-aza-2-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia. The 83-year-old shared on "CBS Sunday Morning" that he's had "a bad experience" while battling multiple myeloma, a blood . Ponatinib, a third-generation TKI with the ability to inhibit most BCR-ABL1 kinase domain mutations, has recently gained approval for resistant Ph-positive ALL. There is a waiver policy for these charges. and JavaScript. OBrien S, Thomas D, Ravandi F, Faderl S, Cortes J, Borthakur G et al. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Raff T, Gkbuget N, Lschen S, Reutzel R, Ritgen M, Irmer S et al. Mortality Benefit of a Blood-Based Biomarker Panel for Lung Cancer on Furthermore, Holmfeldt et al.15 recently described the genetic basis of another subset with poor outcomes, hypodiploid ALL. Blood | Journal | ScienceDirect.com by Elsevier Chung EY, Psathas JN, Yu D, Li Y, Weiss MJ, Thomas-Tikhonenko A. CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis. When considering cases diagnosed within 1 year of blood draw and all noncases, the area under receiver operation characteristics curve estimate of the 4MP + PLCO m2012 model for risk prediction of lung cancer death was 0.88 (95% CI, 0.86 to 0.90). Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. Giessen J, Eckroth E, Malvar J et al. High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia ChromosomeNegative Acute Lymphoblastic Leukemia. Read The Best of the AACR Journals collection, which highlights the most-cited articles from 2021 and 2022. Studies in the pediatric population have identified genetic syndromes that predispose to a minority of cases of ALL, such as Down syndrome, Fanconi anemia, Bloom syndrome, ataxia telangiectasia and Nijmegen breakdown syndrome.4, 5, 6, 7 Other predisposing factors include exposure to ionizing radiation, pesticides, certain solvents or viruses such as Epstein-Barr Virus and Human Immunodeficiency Virus.8, 9, 10 However, in the majority of cases, it appears as a de novo malignancy in previously healthy individuals. Overall response rate was 58%, with similar response between the two dosing schedules. Acute lymphoblastic leukemia has been touted as a major success story in pediatric oncology through the implementation of dose-intensification chemotherapy and Allo-SCT. The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia, Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy. Year. Browse Articles | Blood Cancer Journal - Nature What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? High incidence of Epstein Barr virus infection in childhood acute lymphocytic leukemia: a preliminary study. More recently, fourth-generation CAR-Ts have been engineered to include a cytokine-expressing cassette. In contrast to CALGB 8811, cyclophosphamide is omitted in phase I of induction, but a single dose of intrathecal methotrexate is added for CNS prophylaxis. Preliminary results of nine patients have demonstrated that therapy is well tolerated and produced a sustained remission at 3 months in all three patients treated with a dose level of 1 106 transduced T cells/kg.158, After achieving complete response, treatment options include consolidation and maintenance chemotherapy or Allo-SCT for eligible patients. The MRC UKALL XII/ECOG 299323 regimen utilizes a similar structure to CALGB 8811. Signaling through CD20 plays a role in cell cycle progression, differentiation pathways and regulation of apoptosis. Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH et al. Elderly patients are often unable to tolerate such regimens and carry a particularly poor prognosis. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Heterogeneity of acute lymphoblastic leukemia in HIV-seropositive patients. Furthermore, obinutuzumab was superior in inhibiting growth in NHL xenograft models.107 Awasthi et al.108 compared obinutuzumab to ritixumab in pre-B-ALL cell lines and found obinutuzumab to be superior in inducing cell death and ADCC. Jain N, Lamb AV, O'Brien S, Ravandi F, Konopleva M, Jabbour E et al. PurposePrevious studies have shown that DNA methylation in peripheral blood may be associated with breast cancer (BC). According to new data published today in the Journal of Clinical Oncology, a blood-based four-protein panel (4MP), when combined with a lung cancer risk model (PLCOm2012), can better identify . Ofatumumab is a second-generation anti-CD20 antibody with a distinct binding site from that of rituximab. The .gov means its official. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. The hallmark of ALL is chromosomal abnormalities and genetic alterations involved in differentiation and proliferation of lymphoid precursor cells. Blood Cancer Journal seeks to publish articles of the highest quality related to hematologic malignancies and related disorders. Nordlund J, Backlin CL, Zachariadis V, Cavelier L, Dahlberg J, Ofverholm I et al. Furthermore, elderly patients are particularly susceptible to the dose-limiting toxicities of these agents and are often excluded from Allo-SCT on the basis of performance status and medical comorbidities. ISSN 2044-5385 (online). the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Piccaluga PP, Arpinati M, Candoni A, Laterza C, Paolini S, Gazzola A et al. AACR Journals Metrics | American Association for Cancer Research Impact Factor: According to the Journal Citation ReportsTM (JCR) from ClarivateTM, 2022, Impact Factors for the AACR Journals: Five-Year Impact Factor: As a library, NLM provides access to scientific literature. Both near-haploid and low-hypodiploid exhibited activation of Ras- and PI3K-signaling pathways, suggesting that these pathways may be a target for therapy in aggressive hypodiploid ALL.15. The most significant adverse events include cytokine release syndrome (CRS) and hypotension.111 A phase 2 trial of REGN1979 in relapsed/refractory ALL is currently open for recruitment ({"type":"clinical-trial","attrs":{"text":"NCT02651662","term_id":"NCT02651662"}}NCT02651662). Finally, existing agents, such as bortezomib, decitabine and ruxolitinib that are well tolerated in the treatment of various malignancies are now being studied for application in ALL. Preclinical studies of new compounds, especially those that provide mechanistic insights, Reviews related to new drugs and current management of hematologic malignancies, Novel observations related to new mutations, molecular pathways, and tumor genomics. A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia. Blood Cancer Journal - Academic Accelerator Fujimoto M, Poe JC, Jansen PJ, Sato S, Tedder TF. The JAK/STAT signaling pathway has been identified as a significant mechanism by which leukemic cells bypass normal growth and proliferation restrictions.13 In particular, Ph-like ALL appears to be dependent on JAK signaling. Many cytokine receptors, including IL-7 R, act through JAK kinases as well. Patel B, Kirkwood A, Dey A, Rowntree C, McMillan A, Marks D et al. FOIA Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions. You are using a browser version with limited support for CSS. Sasaki Koji, Ravandi Farhad, Thomas Deborah A, Cortes Jorge E, Pemmaraju Naveen, Kadia Tapan M et al. Jabbour E, O'Brien S, Konopleva M, Kantarjian H. New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia, Acute lymphoblastic leukemia with treatmentnaive Fanconi anemia, Bloom's syndrome. A New Way to Fight Cancer - Scientific American Blog Network Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Presentar un Manuscrito 2 Aos-Factor de Impacto 3 Aos-Factor de Impacto 4 Aos-Factor de Impacto 5 Aos-Factor de Impacto Tiempo Real Factor de Impacto Nuevo Factor de Impacto 2022-2023 9.812 -11.1 % Tendencia del Factor de Impacto In near-haploid (2431 chromosomes) ALL, alterations in tyrosine kinase or Ras signaling was seen in 71% of cases and in IKAROS family zinc finger 3 (IKZF3) in 13% of cases. Use of vincristine and prednisone alone. CD22 is a B-lineage differentiation antigen expressed in B-cell ALL in 50100% of adults and 90% of children.78, 79, 80 Upon binding of an antibody, CD22 is rapidly internalized, thus making it an attractive target for delivering immunotoxin to leukemic cells.81, Epratuzumab is an unconjugated monoclonal antibody targeting CD22 that has been studied in pediatric and adult relapsed/refractory ALL. When compared to treatment with rituximab, treatment with REGN1979 led to significantly more profound depletion of B-cells.110 The safety of REGN1979 was established in a phase 1 trial of 25 patients with NHL and CLL. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL), Minimal residual disease in acute lymphoblastic leukemia. 1New York University School of Medicine, New York, USA, 2Department of Hematology, New York University Perlmutter Cancer Center, New York, USA. Options of salvage therapy for relapsed/refractory (r/r) Ph-negative disease include augmented cytotoxic chemotherapy, reformulated single-agent chemotherapy and novel monoclonal antibodies. Biosis Previews Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X et al. In a phase II study in adults with Ph-negative ALL in their second or greater relapse, VSLI was administered weekly at a dose of 2.25mg/m2.69 Of the 65 adults enrolled, 20% achieved complete response with a median duration of 23 weeks (range 566). 2013; Available at: http://meetinglibrary.asco.org/content/111816-132. Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N et al. Blood Cancer Journal Impact Factor IF 2023|2022|2021 - BioxBio Sasaki K, Kantarjian HM, Ravandi F, Daver N, Kadia TM, Khouri RB et al. Burke MJ, Lamba JK, Pounds S, Cao X, Ghodke-Puranik Y, Lindgren BR et al. The majority of patients were in first salvage and ten patients were primary refractory, and patients with prior exposure to HCVAD were not excluded. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. French-American-British (FAB) co-operative group. Flynn MJ, Berkel PHv, Zammarchi F, Tyrer PC, Akarca AU, Janghra N et al. The addition of rituximab, a first-generation anti-CD20 monoclonal antibody, has improved outcomes in these patients, but resistance to rituximab represents a limitation to its use. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety . Acute lymphoblastic leukemia in early childhood as the presenting sign of ataxia-telangiectasia variant. Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B et al. the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in In the largest prospective trial to determine optimal treatment, MRC UKALL XII/ECOG E2993 found a significant difference of disease-free (DFS) and overall survival (OS) based on age using a cutoff of 35 in Ph-negative disease.23 Similarly, they found an elevated white blood cell count at diagnosis, defined as >30 109 for B-ALL or >100 109 for T-ALL, was an independent prognostic factor for DFS and OS. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL. Maintenance is administered for 23 years after induction, beyond which it has not been shown to have benefit.17, 47. SEER cancer statistics review, 1975-2013:Leukemia, annual incidence rates (acute lymphocytic leukemia). Eligible patients with high-risk disease and a matched donor, then underwent Allo-SCT. In a multivariate analysis of 326 adolescent and adult patients with high-risk Ph-negative ALL treated in The Programa Espanol de Tratamientos en Hematologia (PETHEMA ALL-AR-03), Ribera et al.35 showed that poor MRD clearance, defined as levels >1 103 after induction and levels >5 104 after early consolidation by flow cytometry, was the only significant prognostic factor for disease-free and overall survival. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. The 2022peer review performance metrics forBlood Cancer Journalare shown below: 8 days to first decision for all manuscripts (Median) It is a humanized monoclonal antibody conjugated to a pyrrolobenzodiazepine (PBD). ADCT-301 is a monoclonal antibody against CD25 conjugated to a PBD. A Pilot Survey of Integrative Oncology in Hospitalized Children Journals Blood Cancer Discovery Cancer Discovery Cancer Epidemiology, Biomarkers, & Prevention Cancer Immunology Research Cancer Prevention Research Cancer Research Clinical Cancer Research Molecular Cancer Research Blood Cancer Journal - Nature The landmark study was a multi-center, single-arm, open-label phase 2 trial in which 189 patients with primary refractory and relapsed ALL received single-agent therapy with blinatumomab. In subgroup analysis of 70 patients receiving second salvage therapy with a single agent (most commonly vinorelbine (6), clofarabine (5), nelarabine (4) and topotecan (4)), only 3 achieved a complete response.67, 68 Vincristine sulfate liposomes injection (VSLI) was developed to overcome the dosing and pharmacokinetic limitations of nonliposomal vincristine (VCR). Advani AS, McDonough S, Coutre S, Wood B, Radich J, Mims M et al. Ynez L, Bermdez A, Richard C, Bureo E, Iriondo A. Connect with NLM. Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, FitzGerald DJP, Wilson WH et al. Blood Cancer Journal offers a forum for expedited publication of novel observations regarding new mutations or altered pathways. Blood Cancer Journal (Blood Cancer J.) Recruitment is ongoing for a phase 3 trial of standard chemotherapy with or without bortezomib in children and young adults (age 230) with newly diagnosed T-cell ALL or T-cell lymphoblastic lymphoma ({"type":"clinical-trial","attrs":{"text":"NCT02112916","term_id":"NCT02112916"}}NCT02112916). From magazine subscription chock-full of supportive and easy-to-read articles for cancer patients, and families to books to inspire, this section includes can't-miss free books, magazines, printed organizers, and care journals designed specially to support the needs of cancer patients, caregivers, and families. Department of Leukemia, Houston, Texas, T.U.o.T.M.D.A.C.C. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment. Complete Molecular and Hematologic Response in Adult Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) Following Treatment with Blinatumomab: Results from a Phase 2 Single-Arm, Multicenter Study (ALCANTARA)[Abstract]. Chemotherapy consists of induction, consolidation and long-term maintenance, with CNS prophylaxis given at intervals throughout therapy.